Association between aspirin use and age-related macular degeneration: A meta-analysis

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 4, 2014, Pages 2687-2696

  Ye, Juan ^a   Xu, Yu Feng ^a   He, Jin Jing ^a   Lou, Li Xia ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Age related macular degeneration; Aspirin; Meta analysis

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; FOLLOW UP; HAZARD RATIO; HUMAN; MEDICAL RECORD REVIEW; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RISK; SMOKING;

AGE-RELATED MACULAR DEGENERATION; ASPIRIN; META-ANALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HUMANS; INCIDENCE; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL NEOVASCULARIZATION; RISK FACTORS; WORLD HEALTH;

EID: 84899646397     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13206     Document Type: Article

References (73)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
2. Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology. 2004;111:513-517.
3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. New Engl J Med. 2004;351:2805-2816.
4. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye (Lond). 2005;19:935-944.
5. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA. 1996;276:1147-1151.
6. Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index and the incidence of visually significant agerelated maculopathy in men. Arch Ophthalmol. 2001;119: 1259-1265.
7. Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. Am J Epidemiol. 2002;156:589-598.
8. Klein R, Deng Y, Klein BE, et al. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol. 2007;143:473-483.
9. Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol. 2000;118:351-358.
10. Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, Vernet MH. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol. 2001;8:237-249.
11. Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol. 1994;232: 325-329.
12. Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration. The involvement of giant cells in atrophy of the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1986;27:364-371.
13. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000;70:441-449.
14. Penfold PL, Liew SC, Madigan MC, Provis JM. Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997;38:2125-2133.
15. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and agerelated macular degeneration. Prog Retin Eye Res. 2001;20: 705-732.
16. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000;130:658-663.
17. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115-134.
18. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL III. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112:533-539.
19. Kiernan DF, Hariprasad SM, Rusu IM, Mehta SV, Mieler WF, Jager RD. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina. 2010;30:1573-1578.
20. Klein ML. Macular degeneration: is aspirin a risk for progressive disease? JAMA. 1991;266:2279.
21. Tilanus MA, Vaandrager W, Cuypers MH, Verbeek AM, Hoyng CB. Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2000;238:482-485.
22. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with agerelated macular degeneration. Am J Ophthalmol. 2004;137: 615-624.
23. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci U S A. 2002;99:13371-13373.
24. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
25. Zhu W, Wu Y, Xu D, et al. Aspirin use and risk of age-related macular degeneration: a meta-analysis. PLoS ONE. 2013;8: e58821.
26. Blumenkranz MS, Russell SR, Robey MG, Kott-Blumenkranz R, Penneys N. Risk factors in age-related maculopathy complicated by choroidal neovascularization. Ophthalmology. 1986; 93:552-558.
27. Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2007;114:92-98.
28. Wang JJ, Mitchell P, Smith W, Gillies M, Billson F. Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol. 2003;10:37-48.
29. Hamling J, Lee P, Weitkunat R, Ambuhl M. Facilitating metaanalyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med. 2008;27:954-970.
30. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52: 377-384.
31. Samoocha D, Bruinvels DJ, Elbers NA, Anema JR, van der Beek AJ. Effectiveness of web-based interventions on patient empowerment: a systematic review and meta-analysis. J Med Internet Res. 2010;12:e23.
32. Cheung N, Tay WT, Cheung GC, Wang JJ, Mitchell P, Wong TY. Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye Study. Br J Ophthalmol. 2013;97:785-788.
33. Gemmy Cheung CM, Li X, Cheng CY, et al. Prevalence and risk factors for age-related macular degeneration in Indians: a comparative study in Singapore and India. Am J Ophthalmol. 2013;155:764-773, e763.
34. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of agerelated macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117:921-927.
35. Miyazaki M, Kiyohara Y, Yoshida A, Iida M, Nose Y, Ishibashi T. The 5-year incidence and risk factors for age-related maculopathy in a general Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci. 2005;46:1907-1910.
36. You QS, Xu L, Yang H, et al. Five-year incidence of age-related macular degeneration: the Beijing Eye Study. Ophthalmology. 2012;119:2519-2525.
37. Klein BEK, Howard KP, Gangnon RE, Dreyer JO, Lee KE, Klein R. Long-term use of aspirin and age-related macular degeneration. JAMA. 2012;308:2469-2478.
38. Yang WS, Va P, Wong MY, Zhang HL, Xiang YB. Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies. Am J Clin Nutr. 2011;94: 1575-1583.
39. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology. 2010;74:995-1002.
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
41. Alderson PCS, Higgins JPT, eds. Cochrane reviewers' handbook 4.2.2 [updated March 2004]. In: The Cochrane Library, Issue 1. Chichester: Wiley; 2004:102-153.
42. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315: 629-634.
43. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088-1101.
44. SanGiovanni JP, Chew EY, Sperduto RD, Ferris FL. The relationship of omega-3 long-chain polyunsaturated fatty acid intake and regular aspirin use with neovascular age-related macular degeneration. J Mol Neurosci. 2007;33:142-142.
45. Moon BG, Joe SG, Hwang JU, Kim HK, Choe J, Yoon YH. Prevalence and risk factors of early-stage age-related macular degeneration in patients examined at a health promotion center in Korea. J Korean Med Sci. 2012;27:537-541.
46. Klein R, Knudtson MD, Klein BEK, et al. Inflammation, complement factor H, and age-related macular degeneration: the Multi-ethnic Study of Atherosclerosis. Ophthalmology. 2008;115:1742-1749.
47. de Jong PT, Chakravarthy U, Rahu M, et al. Associations between aspirin use and aging macula disorder: the European Eye Study. Ophthalmology. 2012;119:112-118.
48. Cheung N, Tay WT, Cheung GCM, Wang JJ, Mitchell P, Wong TY. Is aspirin intake associated with early age-related macular degeneration? Clin Exp Ophthalmol. 2012;40:106-107.
49. Hall NF, Martyn CN. Could statins prevent age-related macular degeneration? Expert Opin Pharmacother. 2002;3:803-807.
50. Christen WG Jr. Antioxidants and eye disease. Am J Med. 1994;97:14S-17S.
51. Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE. A case control study of age related macular degeneration and use of statins. Br J Ophthal. 2005;89:1171-1175.
52. Rudnicka AR, MacCallum PK, Whitelocke R, Meade TW. Circulating markers of arterial thrombosis and age-related maculopathy: a case-control study. Br J Haematol. 2009;145: 38.
53. Ajani UA, Christen WG, Manson JE, et al. A prospective study of alcohol consumption and the risk of age-related macular degeneration. Ann Epidemiol. 1999;9:172-177.
54. Klein R, Klein BEK, Jensen SC, et al. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam eye study. Arch Ophthalmol. 2001;119:1354-1359.
55. Chew EY, Clemons T, SanGiovanni JP, et al. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012;119:2282-2289.
56. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A casecontrol study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000; 107:2224-2232.
57. Swanson MW, McGwin G Jr. Anti-inflammatory drug use and age-related macular degeneration. Optom Vis Sci. 2008;85: 947-950.
58. Christen WG, Glynn RJ, Chew EY, Buring JE. Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. Ophthalmology. 2009; 116:2386-2392.
59. Christen WG, Glynn RJ, Ajani UA, et al. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians. Arch Ophthalmol. 2001;119:1143-1149.
60. Liew G, Mitchell P, Wong TY, Rochtchina E, Wang JJ. The association of aspirin use with age-related macular degeneration. JAMA Intern Med. 2013;173:258-264.
61. Rudnicka AR, MacCallum PK, Whitelocke R, Meade TW. Circulating markers of arterial thrombosis and late-stage agerelated macular degeneration: a case-control study. Eye (Lond). 2010;24:1199-1206.
62. Douglas IJ, Cook C, Chakravarthy U, Hubbard R, Fletcher AE, Smeeth L. A case-control study of drug risk factors for agerelated macular degeneration. Ophthalmology. 2007;114: 1164-1169.
63. DeAngelis MM, Lane AM, Shah CP, Ott J, Dryja TP, Miller JW. Extremely discordant sib-pair study design to determine risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 2004;122:575-580.
64. Sharpe D. Of apples and oranges, file drawers and garbage: why validity issues in meta-analysis will not go away. Clin Psychol Rev. 1997;17:881-901.
65. de Jong PT. Age-related macular degeneration. New Engl J Med. 2006;355:1474-1485.
66. Maloney SC, Fernandes BF, Castiglione E, et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina. 2009;29: 176-180.
67. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073-3076.
68. Wong TY, Klein R, Sun C, et al. Age-related macular degeneration and risk for stroke. Ann Intern Med. 2006;145: 98-106.
69. Grosser N, Schroder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol. 2003;23:1345-1351.
70. Cheung N, Liao D, Islam FM, Klein R, Wang JJ, Wong TY. Is early age-related macular degeneration related to carotid artery stiffness? The Atherosclerosis Risk in Communities Study. Br J Ophthalmol. 2007;91:430-433.
71. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887-896.
72. Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011; 118:1359-1369.
73. Hansch GM, Romer W, Voigtlander V, Rother U. Effect of salicylates on the complement system: generation of mediators in vivo and in vitro. Clin Immunol Immunopathol. 1981; 21:228-236.